Catalent Inc (NYSE:CTLT)
$ 54.82 -0.25 (-0.45%) Market Cap: 9.92 Bil Enterprise Value: 14.79 Bil PE Ratio: 0 PB Ratio: 2.75 GF Score: 83/100

Catalent Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 01:20PM GMT
Release Date Price: $115.4 (+2.59%)
Tycho W. Peterson
JPMorgan Chase & Co, Research Division - Senior Analyst

All right. Good morning, everybody. Welcome to day 1 of the JPMorgan Healthcare Conference. I'm pleased to introduce our next company, Catalent. (Operator Instructions)

And with that, let me turn it over to John.

John R. Chiminski
Catalent, Inc. - Chairman & CEO

Great. Thanks, Tycho. Good morning, everybody. I'm pleased to be with you in this virtual format to share Catalent's story.

Before diving into the presentation, let me first draw your attention to Slides #2 and 3, which note our forward-looking statements and also non-GAAP financials. I also encourage you to review our SEC filings to understand the risks and uncertainties that may bear on our operating results and financial condition.

So let's turn to Page 4. For decades, Catalent has been the leading global provider of advanced dosage delivery technologies and drug development and manufacturing solutions. As a leading CDMO, we continue to differentiate ourselves through investing in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot